Welcome to our dedicated page for Neurocrine Biosciences SEC filings (Ticker: NBIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Neurocrine Biosciences Inc (Nasdaq: NBIX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware-incorporated, publicly traded biopharmaceutical company, Neurocrine Biosciences reports its financial performance, material events and key corporate developments through forms such as 10-K annual reports, 10-Q quarterly reports and 8-K current reports.
In its recent Form 8-K filings, Neurocrine Biosciences has reported quarterly financial results, including net product sales for INGREZZA and CRENESSITY, research and development and selling, general and administrative expenses, and net income. These filings often incorporate press releases that discuss revenue trends, non-GAAP financial measures, R&D investment in programs such as osavampator and direclidine, and updates on collaborations. Other 8-K items may cover executive and board-related matters, such as amendments to employment agreements and changes in key leadership roles.
On this page, investors can review the full text of Neurocrine Biosciences’ periodic reports to understand how the company describes its business, risk factors, product portfolio and pipeline. The annual Form 10-K typically includes detailed sections on therapeutic focus areas like tardive dyskinesia, Huntington’s disease chorea, classic congenital adrenal hyperplasia, endometriosis and uterine fibroids, as well as discussion of the company’s neuroscience and endocrinology research strategy. Quarterly Form 10-Q filings update these disclosures and provide interim financial statements.
Stock Titan enhances these documents with AI-powered summaries that highlight the most important points from lengthy filings, helping readers quickly identify changes in revenue composition, R&D spending, collaboration milestones and other material items. Users can also monitor real-time 8-K updates for new clinical data announcements, financing activities or governance changes, and access Form 4 insider transaction reports to see how company insiders are trading NBIX shares, when such filings are available.
Whether you are evaluating Neurocrine Biosciences’ exposure to specific therapeutic areas, following its investment in late-stage programs like osavampator and direclidine, or comparing GAAP and non-GAAP results, this filings page offers a structured view of the company’s official SEC record with tools that make complex disclosures easier to interpret.
Vanguard Capital Management filed a Schedule 13G reporting beneficial ownership of 5,257,941 shares of Neurocrine Biosciences common stock, representing 5.23% of the class as of 03/31/2026. The filing states Vanguard Capital Management LLC and specified Vanguard affiliates exercise dispositive power over these shares and that holdings include securities held for Vanguard funds and managed clients. The statement is signed by Ashley Grim, Head of Global Fund Administration, on 04/30/2026.
Neurocrine Biosciences and its subsidiary Sigma Merger Sub have amended their tender offer for Soleno Therapeutics, offering $53.00 per share in cash for all outstanding common shares. This Amendment No. 2 supplements the Schedule TO and adds a Soleno Employee FAQ as an exhibit, with other offer terms remaining as filed.
Neurocrine Biosciences and its subsidiary Sigma Merger Sub have amended their tender offer for Soleno Therapeutics, offering $53.00 per share in cash for all outstanding common shares. This Amendment No. 2 supplements the Schedule TO and adds a Soleno Employee FAQ as an exhibit, with other offer terms remaining as filed.
Neurocrine Biosciences has amended its Schedule TO to confirm the tender offer by its subsidiary Sigma Merger Sub to acquire all outstanding Soleno Therapeutics common shares for $53.00 per share, payable in cash. The filing states the HSR Act waiting period expired as of April 27, 2026, satisfying the Regulatory Condition to the Offer; the Offer remains subject to the remaining conditions set forth in the Offer to Purchase.
Neurocrine Biosciences has amended its Schedule TO to confirm the tender offer by its subsidiary Sigma Merger Sub to acquire all outstanding Soleno Therapeutics common shares for $53.00 per share, payable in cash. The filing states the HSR Act waiting period expired as of April 27, 2026, satisfying the Regulatory Condition to the Offer; the Offer remains subject to the remaining conditions set forth in the Offer to Purchase.
Neurocrine Biosciences, Inc. is conducting a cash tender offer to acquire Soleno Therapeutics, Inc. at $53.00 per share under the Offer to Purchase dated April 20, 2026. The offer, made by Neurocrine's wholly owned subsidiary Sigma Merger Sub, Inc., covers all outstanding Soleno common shares.
The Offer to Purchase, Letter of Transmittal and related transaction agreements (including an Agreement and Plan of Merger dated April 5, 2026) are attached as exhibits and incorporated by reference. The offer is payable in cash, subject to customary terms, conditions and any applicable withholding taxes; the filing states the Offer is not subject to a financing condition.
Neurocrine Biosciences, Inc. is conducting a cash tender offer to acquire Soleno Therapeutics, Inc. at $53.00 per share under the Offer to Purchase dated April 20, 2026. The offer, made by Neurocrine's wholly owned subsidiary Sigma Merger Sub, Inc., covers all outstanding Soleno common shares.
The Offer to Purchase, Letter of Transmittal and related transaction agreements (including an Agreement and Plan of Merger dated April 5, 2026) are attached as exhibits and incorporated by reference. The offer is payable in cash, subject to customary terms, conditions and any applicable withholding taxes; the filing states the Offer is not subject to a financing condition.
Neurocrine Biosciences, Inc. will hold its 2026 annual stockholders’ meeting on May 27, 2026 at 10:30 a.m. in San Diego. Stockholders of record as of March 31, 2026, when 100,581,991 common shares were outstanding, may vote.
They are being asked to elect three Class III directors, cast an advisory vote on executive compensation, and approve an amendment to the 2025 Equity Incentive Plan that would increase shares reserved for issuance by 4,000,000. Investors will also vote on ratifying Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026. The Board recommends voting “for” all four proposals and highlights a range of governance practices, including proxy access, a clawback policy, and a classified board structure.
Neurocrine Biosciences has announced a planned tender offer by its wholly owned subsidiary, Sigma Merger Sub, for all outstanding shares of Soleno Therapeutics, Inc., pursuant to an Agreement and Plan of Merger dated April 5, 2026. The communication states the tender offer has not commenced and that formal tender offer materials and Soleno’s solicitation/recommendation on Schedule 14D-9 will be filed with the SEC when the offer begins. Forward-looking statements and customary closing conditions are included; timing, price, and the number of shares to be acquired are not provided in the excerpt.
Neurocrine Biosciences has announced a planned tender offer by its wholly owned subsidiary, Sigma Merger Sub, for all outstanding shares of Soleno Therapeutics, Inc., pursuant to an Agreement and Plan of Merger dated April 5, 2026. The communication states the tender offer has not commenced and that formal tender offer materials and Soleno’s solicitation/recommendation on Schedule 14D-9 will be filed with the SEC when the offer begins. Forward-looking statements and customary closing conditions are included; timing, price, and the number of shares to be acquired are not provided in the excerpt.
Neurocrine Biosciences and its acquisition subsidiary, Sigma Merger Sub, intend to launch a tender offer for all outstanding shares of Soleno Therapeutics, Inc. The planned tender offer is to be made pursuant to an Agreement and Plan of Merger, dated April 5, 2026. The communication describes procedural next steps: a Schedule TO tender offer statement to be filed by Neurocrine and its acquisition subsidiary and a Schedule 14D-9 solicitation/recommendation statement to be filed by Soleno; the offer has not commenced.
The statement includes customary forward-looking disclaimers about timing, closing conditions, potential competing proposals, regulatory uncertainty, integration risks, and other standard transaction risks.
Neurocrine Biosciences and its acquisition subsidiary, Sigma Merger Sub, intend to launch a tender offer for all outstanding shares of Soleno Therapeutics, Inc. The planned tender offer is to be made pursuant to an Agreement and Plan of Merger, dated April 5, 2026. The communication describes procedural next steps: a Schedule TO tender offer statement to be filed by Neurocrine and its acquisition subsidiary and a Schedule 14D-9 solicitation/recommendation statement to be filed by Soleno; the offer has not commenced.
The statement includes customary forward-looking disclaimers about timing, closing conditions, potential competing proposals, regulatory uncertainty, integration risks, and other standard transaction risks.
Neurocrine Biosciences entered into an Agreement and Plan of Merger to acquire Soleno Therapeutics via a cash tender offer at $53.00 per share. Neurocrine will commence the offer within ten business days and keep it open for twenty business days, subject to customary conditions, antitrust clearances and possible extensions.
The agreement contemplates a subsequent short-form merger under Section 251(h) of the DGCL; certain Soleno equity awards, RSUs and warrants will be cashed out at the Offer Price or treated per their terms. The merger agreement includes a $95,250,000 termination fee and a $141,500,000 reverse termination fee. Supporting stockholders hold approximately 1.01% of Soleno shares.
Neurocrine Biosciences entered into an Agreement and Plan of Merger to acquire Soleno Therapeutics via a cash tender offer at $53.00 per share. Neurocrine will commence the offer within ten business days and keep it open for twenty business days, subject to customary conditions, antitrust clearances and possible extensions.
The agreement contemplates a subsequent short-form merger under Section 251(h) of the DGCL; certain Soleno equity awards, RSUs and warrants will be cashed out at the Offer Price or treated per their terms. The merger agreement includes a $95,250,000 termination fee and a $141,500,000 reverse termination fee. Supporting stockholders hold approximately 1.01% of Soleno shares.
Neurocrine Biosciences agreed to acquire Soleno Therapeutics via a cash tender offer at $53.00 per share, valuing Soleno’s equity at $2.9 billion. The price reflects a 34% premium to Soleno’s April 2, 2026 close and a 51% premium to its 30‑day VWAP. After the tender offer, any remaining Soleno shares will be converted into the same cash amount through a follow‑on merger, making Soleno a wholly owned Neurocrine subsidiary.
The deal is funded with cash on hand plus modest pre‑payable debt and is not subject to a financing condition, but it requires a majority of Soleno shares to be tendered and clearance under the Hart‑Scott‑Rodino Act. Soleno must observe no‑shop restrictions, with a $95.25 million termination fee if it moves to a superior proposal and a $141.5 million reverse termination fee payable by Neurocrine if certain antitrust conditions are not met. Neurocrine highlights Soleno’s VYKAT XR, which generated $190 million of 2025 revenue, as a way to expand its endocrinology and rare‑disease portfolio and add a third first‑in‑class commercial medicine.